Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.
Ontology highlight
ABSTRACT: Cytogenetically normal acute myeloid leukemia (CN-AML) is a heterogeneous disease with variable clinical outcomes. Emerging data has identified molecular markers that provide additional prognostic information to better classify these patients into those with a more favorable prognosis and those with an unfavorable prognosis who may require more aggressive or investigational therapies. Markers such as mutations in nucleophosmin 1 gene and CCAAT/enhancer binding protein alpha gene have been associated with a more favorable prognosis in CN-AML. In contrast, FMS-related tyrosine kinase 3 mutations, partial tandem duplication of mixed-lineage leukemia gene and overexpression of brain and acute leukemia, cytoplasmic gene are associated with inferior clinical outcomes. In this article, the author
SUBMITTER: Lin TL
PROVIDER: S-EPMC4234091 | biostudies-literature | 2011 May
REPOSITORIES: biostudies-literature
ACCESS DATA